

JUL 18 2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence Listing as required by 37 C.F.R. 1.821(c).
- 3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up Raw Sequence Listing.
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the Sequence Listing is not the same as the computer readable from of the Sequence Listing as required by 37 C.F.R. 1.821(e).
- 7. Other: Figures 3.1 and 3.2 contain sequences without the requisite sequence identifiers.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the Sequence Listing..
- An initial or substitute paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



3495.0178-01

16TM/SMP

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In Re Application of: Ladant et al.

Serial No.: Not yet assigned

Filed: October 10, 2001

For: BACTERIAL MULTI-HYBRID SYSTEM AND APPLICATIONS THEREOF

Group Art Unit in parent case: 1645

Examiner in parent case: R. Zeman

1. Check for \$920.00
2. Request for Divisional Application, with copy of parent application as-filed
3. Preliminary Amendment with 4 p. sequence listing and 9 p. appendix
4. Request for Transfer of Form Under 37 C.F.R. 1.821(e)
5. Request for Approval of Drawing Change with 3 sheets of Figs.
6. Submission of Formal Drawings with 7 sheets of Figs. 1-6
7. Power of Attorney/Declaration from parent application

Dated October 10, 2001

Docket No.: 03495.0178-01

SMP/DL Long Mail Drop 884

(Due Date: 10/10/01)



200 10.10.01 T



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 18 2006
PATENT & TRADEMARK OFFICE
USPTO

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAME INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/973,013	10/10/2001	Daniel Ladant	3495-0178-01	4881

22852 7590 06/19/2006
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413

RECEIVED

JUN 21 2006

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.

EXAMINER	
ZEMAN, ROBERT A	
ART UNIT	PAPER NUMBER
1645	

DATE MAILED: 06/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Docketed 6/21/06 Attorney KJM/DUK
Case 5394-0023
Due Date 8/19/06 all exts
Action Nucleotide due
By SJ JR



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO/CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
09/973,013			



EXAMINER

Robert A. Zeman

ART UNIT

PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

ROBERT ZEMAN
PATENT EXAMINER



1645

PATENT
Customer No. 22,852
Attorney Docket No. 05394-0023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
LADANT et al.) Group Art Unit: 1645
Application No.: 09/973,013) Examiner: Zeman, Robert A.
Filed: October 10, 2001) Confirmation No.: 4881
For: BACTERIAL MULTI-HYBRID)
SYSTEM AND APPLICATIONS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO NOTICE TO COMPLY

In a Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed June 19, 2006, the Office asserted that Figures 3.1 and 3.2 contain sequences without the requisite sequence identifiers. In response, Applicants have attached copies of Figures 3.1 and 3.2, which were filed on October 10, 2001, as indicated on the stamped postcard, a copy of which is also attached. These Figures include sequence identifiers for SEQ ID NOS: 6-11, which are depicted in Figures 3.1 and 3.2. Accordingly, Applicants respectfully submit that the sequence requirements have been fulfilled.


Please grant any further extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 18, 2006

By:


Deborah Katz
Reg. No. 51,863
Phone: (202) 408-4382
Fax: (202) 408-4400
E-mail: deborah.katz@finnegan.com

Attachments: Copies of Figures 3.1 and 3.2
Copy of stamped postcard
Copy of Notice to Comply